Genmab — Februar 2018

Teller

Hello, I am new to this chat, but I have been following it for more than a year now.

Bulder

Yes, or the US-equivalent to VMp: CyBorD

Teller

Maybe the higher price simply reflects a higher demand?

Bulder

The higher the Rev-price goes, the more important is the Dara+CyborD-study, from which we should see data soon.

Teller

Solsen - Hvilken dosis (stand alone eller combo) er denne aarlige behandlingspris baseret paa?

E_L

how much does
CyborD cost?

Bulder

The only drug of the three still patented is bor (Velcade), and it will run out of patent in Europe next year.

Bulder

One unit is DKK 10.051 https://min.medicin.dk/Medicin/Praeparater/3370

Teller

Hvis der anvendes lavere dosis i combo behandling med dara, bliver det vel ikke noedvendigvis mere omkosteligt at behandle. (ud over de +20% om aaret som mere eller mindre er normalen)

Teller

(www.chicagotribune.com)

Bulder

Later this year we

Bulder

... we'll have data from the Cassiopeia study with thalidomide in stead of lenalidomide. So no wonder Celgene raises prices before it's too late.

Solsen

Yes thats what it is. Short CELG

Bulder

The Irish MD, with whom I saw a video the other day, spoke about "financial toxicity", meaning that they wouldn't dream of paying for a Rev-containing combo with dara. And therefore they run their own local Irish study of dara+CyBorD.

E_L

Solsen

I also think it will kill CELG in the long run. And perhaps you are right that they have seen the end and use the time up to that to get the best outcome.

Solsen

https://clinicaltrials.gov/ct2/show/NCT02951819?recrs=a&cond=Daratumumab&draw=4&rank=37 Data could be due in this CyBorD+Dara

Thomas

Der nævnes ofte at Gen guider konservativt, det er da uden hold i virkeligheden. Så måske vi alle skulle tage deres guidance ganske seriøst...

Thomas

Tillader mig at poste dette link fra forleden igen http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=765390&isEPVantage=yes

Thomas

Også her tales der om at Revlimid efterhånden opfattes som en konkurrent. Det er efterhånden et lidt andet billede end der har været tegnet for 1-2 år siden hvor mere så Revlimid som en ‘ven’. Tager jeg fejl?